Fangzhou Inc.: A New Era in AI-Driven Healthcare
March 27, 2025, 6:11 am
Fangzhou Inc. is not just a name in the healthcare sector; it’s a beacon of innovation. The company has emerged as a leader in Internet healthcare solutions, harnessing the power of artificial intelligence (AI) to reshape chronic disease management (CDM) in China. With its recent financial results and strategic partnerships, Fangzhou is poised for a transformative journey.
In March 2025, Fangzhou reported a revenue of RMB 2.7 billion for the fiscal year 2024, marking an 11.2% increase from the previous year. The adjusted net profit soared by 139%, reaching RMB 17.2 million. This growth is not merely a number; it’s a testament to the company’s commitment to technological advancement and operational efficiency. Fangzhou’s founder and CEO, Dr. Xie Fangmin, emphasized the importance of aligning with national policies and leveraging AI to create a patient-centered ecosystem.
The company’s mission is clear: to drive innovation through AI. In 2024, Fangzhou ramped up its research and development efforts, focusing on large language models, big data, and cloud computing. These innovations have significantly improved chronic disease management across its platform. The results speak volumes. Registered users on the Jianke Platform reached 49.2 million, with average monthly active users climbing 20% year-on-year to 10.1 million. The repeat purchase rate among paying users remained robust at 84.7%. This indicates not just growth, but a deepening engagement with users.
Fangzhou’s physician network is another pillar of its success. The company expanded its registered physician base to 223,000, with a significant portion affiliated with Class III hospitals. This expansion is crucial. It enhances the quality of care and ensures that patients receive expert guidance. Fangzhou also introduced a sales force automation system to better understand and meet the needs of physicians in underserved regions.
The company’s online retail pharmacy services saw an 8.3% revenue increase, reaching RMB 1.405 billion. Customized content and marketing solutions also grew by 20.7%. These figures illustrate Fangzhou’s diverse revenue streams and its ability to adapt to market demands.
Supply chain advancements are another feather in Fangzhou’s cap. The company collaborates with over 1,500 suppliers and more than 900 pharmaceutical companies. This extensive network allows Fangzhou to offer nearly 215,000 drug SKUs, with a significant portion being prescription drugs. Such a robust supply chain is vital for ensuring that patients have access to the medications they need.
Looking ahead, Fangzhou is not resting on its laurels. The company has set its sights on 2025 with a multi-faceted strategy. Key priorities include enhancing AI capabilities, improving user experience, and optimizing supply chain operations. Talent acquisition will also play a crucial role in driving innovation and growth.
In a bold move, Fangzhou recently partnered with Tencent Health and Tencent Cloud to accelerate the development of AI-enabled healthcare services. This collaboration aims to integrate the DeepSeek open-source AI model into Fangzhou’s platform. The upgraded “AI Agent 2.0” will enhance pharmaceutical logistics and online healthcare services. This partnership is a game-changer. It combines Fangzhou’s healthcare expertise with Tencent’s technological prowess, paving the way for smarter, more efficient solutions.
DeepSeek’s architecture is designed for scalability and efficiency. Its Mixture-of-Experts (MoE) model ensures that Fangzhou can handle increased demand without compromising on performance. Moreover, the private deployment of DeepSeek ensures compliance with data privacy regulations, a critical factor in today’s digital landscape.
The deployment of “AI Agent 2.0” signifies a milestone in Fangzhou’s journey. This system focuses on two core areas: patient services and physician workflows. By enhancing these areas, Fangzhou aims to deliver a seamless experience for both patients and healthcare providers.
Fangzhou’s trajectory is not just about numbers; it’s about impact. The company is dedicated to improving the lives of chronic disease patients through tailored medical care and precision medicine. With 49.2 million registered users and 223,000 physicians on its platform, Fangzhou is well-positioned to lead the charge in AI-driven healthcare.
As Fangzhou continues to innovate and expand, it stands as a testament to the potential of technology in healthcare. The company’s commitment to AI-powered solutions is not just a strategy; it’s a vision for the future. In a world where healthcare is increasingly digital, Fangzhou is at the forefront, shaping the landscape of chronic disease management in China.
In conclusion, Fangzhou Inc. is more than a healthcare provider; it’s a pioneer. With its strong financial performance, strategic partnerships, and unwavering focus on innovation, the company is set to redefine the healthcare experience for millions. The future is bright, and Fangzhou is leading the way.
In March 2025, Fangzhou reported a revenue of RMB 2.7 billion for the fiscal year 2024, marking an 11.2% increase from the previous year. The adjusted net profit soared by 139%, reaching RMB 17.2 million. This growth is not merely a number; it’s a testament to the company’s commitment to technological advancement and operational efficiency. Fangzhou’s founder and CEO, Dr. Xie Fangmin, emphasized the importance of aligning with national policies and leveraging AI to create a patient-centered ecosystem.
The company’s mission is clear: to drive innovation through AI. In 2024, Fangzhou ramped up its research and development efforts, focusing on large language models, big data, and cloud computing. These innovations have significantly improved chronic disease management across its platform. The results speak volumes. Registered users on the Jianke Platform reached 49.2 million, with average monthly active users climbing 20% year-on-year to 10.1 million. The repeat purchase rate among paying users remained robust at 84.7%. This indicates not just growth, but a deepening engagement with users.
Fangzhou’s physician network is another pillar of its success. The company expanded its registered physician base to 223,000, with a significant portion affiliated with Class III hospitals. This expansion is crucial. It enhances the quality of care and ensures that patients receive expert guidance. Fangzhou also introduced a sales force automation system to better understand and meet the needs of physicians in underserved regions.
The company’s online retail pharmacy services saw an 8.3% revenue increase, reaching RMB 1.405 billion. Customized content and marketing solutions also grew by 20.7%. These figures illustrate Fangzhou’s diverse revenue streams and its ability to adapt to market demands.
Supply chain advancements are another feather in Fangzhou’s cap. The company collaborates with over 1,500 suppliers and more than 900 pharmaceutical companies. This extensive network allows Fangzhou to offer nearly 215,000 drug SKUs, with a significant portion being prescription drugs. Such a robust supply chain is vital for ensuring that patients have access to the medications they need.
Looking ahead, Fangzhou is not resting on its laurels. The company has set its sights on 2025 with a multi-faceted strategy. Key priorities include enhancing AI capabilities, improving user experience, and optimizing supply chain operations. Talent acquisition will also play a crucial role in driving innovation and growth.
In a bold move, Fangzhou recently partnered with Tencent Health and Tencent Cloud to accelerate the development of AI-enabled healthcare services. This collaboration aims to integrate the DeepSeek open-source AI model into Fangzhou’s platform. The upgraded “AI Agent 2.0” will enhance pharmaceutical logistics and online healthcare services. This partnership is a game-changer. It combines Fangzhou’s healthcare expertise with Tencent’s technological prowess, paving the way for smarter, more efficient solutions.
DeepSeek’s architecture is designed for scalability and efficiency. Its Mixture-of-Experts (MoE) model ensures that Fangzhou can handle increased demand without compromising on performance. Moreover, the private deployment of DeepSeek ensures compliance with data privacy regulations, a critical factor in today’s digital landscape.
The deployment of “AI Agent 2.0” signifies a milestone in Fangzhou’s journey. This system focuses on two core areas: patient services and physician workflows. By enhancing these areas, Fangzhou aims to deliver a seamless experience for both patients and healthcare providers.
Fangzhou’s trajectory is not just about numbers; it’s about impact. The company is dedicated to improving the lives of chronic disease patients through tailored medical care and precision medicine. With 49.2 million registered users and 223,000 physicians on its platform, Fangzhou is well-positioned to lead the charge in AI-driven healthcare.
As Fangzhou continues to innovate and expand, it stands as a testament to the potential of technology in healthcare. The company’s commitment to AI-powered solutions is not just a strategy; it’s a vision for the future. In a world where healthcare is increasingly digital, Fangzhou is at the forefront, shaping the landscape of chronic disease management in China.
In conclusion, Fangzhou Inc. is more than a healthcare provider; it’s a pioneer. With its strong financial performance, strategic partnerships, and unwavering focus on innovation, the company is set to redefine the healthcare experience for millions. The future is bright, and Fangzhou is leading the way.